Biomarkers to Predict Antidepressant Response
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
During the past several years, we have achieved a deeper understanding of the etiology/pathophysiology of major depressive disorder (MDD). However, this improved understanding has not translated to improved treatment outcome. Treatment often results in symptomatic improvement, but not full recovery. Clinical approaches are largely trial-and-error, and when the first treatment does not result in recovery for the patient, there is little proven scientific basis for choosing the next. One approach to enhancing treatment outcomes in MDD has been the use of standardized sequential treatment algorithms and measurement-based care. Such treatment algorithms stand in contrast to the personalized medicine approach, in which biomarkers would guide decision making. Incorporation of biomarker measurements into treatment algorithms could speed recovery from MDD by shortening or eliminating lengthy and ineffective trials. Recent research results suggest several classes of physiologic biomarkers may be useful for predicting response. These include brain structural or functional findings, as well as genomic, proteomic, and metabolomic measures. Recent data indicate that such measures, at baseline or early in the course of treatment, may constitute useful predictors of treatment outcome. Once such biomarkers are validated, they could form the basis of new paradigms for antidepressant treatment selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“The results from this second level of treatment showed numeric superiority for switching to medications with a different MOA and slightly more so for combining treatments with different MOAs, although none of these differences reached statistical significance [11, 12 ].”
BackgroundSelf-citationA Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375 · cited 1×
“Of all serum protein measures, BDNF is the most clearly implicated in the pathogenesis and treatment of MDD [ 85 ].”
BackgroundThe Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Sheline, Y. I., Barch, D. M., Donnelly, J. M., Ollinger, J. M., Snyder, A. Z., & Mintun, M. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01263-x · Cited by 1,191 · cited 1×
“Increased reactivity seems to normalize after successful antidepressant pharmacotherapy [39, 40] and cognitivebehavioral therapy [41], and may be a sufficiently consistent finding to be of eventual clinical utility.”
BackgroundMayberg, H. S. (2003) · British Medical Bulletin · doi:10.1093/bmb/65.1.193 · Cited by 1,166 · cited 1×
“These abnormalities may be associated with poorer outcome because they impair mood regulatory interactions between prefrontal and limbic areas [29].”
BackgroundBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 9×
“The current widespread use of SSRIs in treatment of depression has resulted in a large body of literature on SSRI pharmacogenetics [65].”
BackgroundInfluentialMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 9×
“Because most patients fail to enter remission with the first antidepressant prescribed [4], they then commonly enter a period of serial trial-anderror, using switches in or combinations of medications [5] and typically taking 1 year or more to hit upon a successful treatment [6, 7].”
BackgroundInfluentialSelf-citationBrunoni, A. R., Lopes, M., & Fregni, F. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009309 · Cited by 972 · cited 1×
“There is strong evidence of low serum BDNF in unmedicated MDD patients and recovery of serum BDNF levels after antidepressant therapy [ 87 ], including in a large meta-analysis [88].”
MethodKoolschijn, P. C. M. P., van Haren, N. E. M., Lensvelt‐Mulders, G. J. L. M., Hulshoff Pol, H. E., & Kahn, R. S. (2009) · Human Brain Mapping · doi:10.1002/hbm.20801 · Cited by 902
Mapping complex disease traits with global gene expression
Cookson, W., Liang, L., Abecasis, G., Moffatt, M., & Lathrop, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2537 · Cited by 849 · cited 1×
“These expression quantitative trait loci are a powerful resource for complex disease gene mapping, as recently reviewed by Cookson et al. [ 80 ].”
BackgroundAnand, A., Li, Y., Wang, Y., Wu, J., Gao, S., Bukhari, L., Mathews, V. P., Kalnin, A., & Lowe, M. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.021 · Cited by 787
Fu, C. H. Y., Williams, S. C. R., Cleare, A. J., Brammer, M. J., Walsh, N. D., Kim, J., Andrew, C. M., Pich, E. M., Williams, P. M., Reed, L. J., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.9.877 · Cited by 775
McKinnon, M. C., Yucel, K., Nazarov, A., & MacQueen, G. M. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0905 · Cited by 742
Surguladze, S., Brammer, M. J., Keedwell, P., Giampietro, V., Young, A. W., Travis, M. J., Williams, S. C. R., & Phillips, M. L. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.028 · Cited by 633 · cited 1×
“When viewing negative facial expressions, depressed patients show exaggerated changes in activity in the limbic system, particularly the amygdala, in comparisonwith healthy controls [35].”
BackgroundPizzagalli, D., Pascual-Marqui, R. D., Nitschke, J. B., Oakes, T. R., Larson, C. L., Abercrombie, H. C., Schaefer, S. M., Koger, J. V., Benca, R. M., & Davidson, R. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.405 · Cited by 630 · cited 1×
“brain activity not only on the cortical convexities but also in deeper specific cortical areas (eg, the ACC and medial orbitofrontal cortex) [61].”
BackgroundThe neural substrates of affective processing in depressed patients treated with venlafaxine
Davidson, R. J., Irwin, W., Anderle, M. J., & Kalin, N. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.64 · Cited by 487
Asada, H., Fukuda, Y., Tsunoda, S., Yamaguchi, M., & Tonoike, M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00679-5 · Cited by 411 · cited 1×
“While cordance may in fact reflect activity of areas such as the ACC that is projected to the surface [62], LORETA permits attribution of electrical activity to specific deeper structures.”
BackgroundContinuity of antidepressant treatment for adults with depression in the United States
Olfson, M., Marcus, S. C., Tedeschi, M., & Wan, G. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.101 · Cited by 392 · cited 1×
“It is not surprising that using this “hit-ormiss” approach, 26% of those who fail to improve with the first treatment simply stop taking medication, frequently within the first 2 weeks [8], and up to 42% of patients discontinue medication within the first 30 days [9].”
MethodChoi, J., Jeong, B., Rohan, M. L., Polcari, A. M., & Teicher, M. H. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.022 · Cited by 376 · cited 1×
“The integrity of these corticolimbic pathways is adversely impacted by adverse life events [30] as well as genetic polymorphisms (eg, 5-HTTLPR) [31].”
BackgroundFu, C. H. Y., Williams, S. C. R., Cleare, A. J., Scott, J., Mitterschiffthaler, M. T., Walsh, N. D., Donaldson, C., Suckling, J., Andrew, C., Steiner, H., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.033 · Cited by 349 · cited 1×
“Increased reactivity seems to normalize after successful antidepressant pharmacotherapy [39, 40] and cognitivebehavioral therapy [41], and may be a sufficiently consistent finding to be of eventual clinical utility.”
BackgroundAntidepressant Effect on Connectivity of the Mood-Regulating Circuit: An fMRI Study
Anand, A., Li, Y., Wang, Y., Wu, J., Gao, S., Bukhari, L., Mathews, V. P., Kalnin, A., & Lowe, M. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300725 · Cited by 324 · cited 1×
“Anand and colleagues [34] also showed that corticolimbic connectivity increased as scores on the Hamilton Depression Rating Scale decreased during treatment, suggesting that assessment of resting state corticolimbic connectivity could be useful for predicting antidepressant treatment response.”
BackgroundPapakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308 · cited 1×
“Although some data suggest that subsets of patients may be more likely to benefit from medications with particular MOAs, the number needed to treat (NNT) to see such differences can be so large (NNT = 27) [10] that the value is questionable.”
BackgroundFrodl, T., Jäger, M., Smajstrlova, I., Born, C., Bottlender, R., Palladino, T., Reiser, M., Möller, H.-J., & Meisenzahl, E. M. (2008) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0840 · Cited by 279
Sartorius, A., Hellweg, R., Litzke, J., Vogt, M., Dormann, C., Vollmayr, B., Danker-Hopfe, H., & Gass, P. (2009) · Pharmacopsychiatry · doi:10.1055/s-0029-1224162 · Cited by 276
MacQueen, G. M., Yucel, K., Taylor, V. H., Macdonald, K., & Joffe, R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.027 · Cited by 274 · cited 1×
“The most robust evidence is for the hippocampus, for which larger volumes predicted better response after 8 weeks of pharmacotherapy in two separate samples [22, 23].”
BackgroundPrognostic and diagnostic potential of the structural neuroanatomy of depression
Costafreda, S. G., Chu, C., Ashburner, J., & Fu, C. H. Y. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006353 · Cited by 232 · cited 1×
“The predictive utility of structural data is not limited to the hippocampus, as gray matter density in the ACC and posterior cingulate cortex was also predictive of clinical remission following 8 weeks of fluoxetine treatment [26].”
BackgroundFunctional Coupling of the Amygdala in Depressed Patients Treated with Antidepressant Medication
Chen, C.-H., Suckling, J., Ooi, C., Fu, C. H. Y., Williams, S. C. R., Walsh, N. D., Mitterschiffthaler, M. T., Pich, E. M., & Bullmore, E. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301593 · Cited by 224 · cited 1×
“In a treatment study, 8 weeks of fluoxetine administration ameliorated the deficient connections between the amygdala and anterior cingulate [43].”
BackgroundAnand, A., Li, Y., Wang, Y., Gardner, K., & Lowe, M. J. (2007) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.19.3.274 · Cited by 215 · cited 1×
“These changes in task-related reactivity are complementary to differences between treatment responders and nonresponders in resting state connectivity within corticolimbic circuits [44].”
BackgroundMatthews, S. C., Strigo, I. A., Simmons, A. N., Yang, T. T., & Paulus, M. P. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.05.022 · Cited by 190
Altered gene expression of histone deacetylases in mood disorder patients
Hobara, T., Uchida, S., Otsuki, K., Matsubara, T., Funato, H., Matsuo, K., Suetsugi, M., & Watanabe, Y. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.08.015 · Cited by 185
A preliminary metabolomic analysis of older adults with and without depression
Paige, L. A., Mitchell, M. W., Krishnan, K. R. R., Kaddurah‐Daouk, R., & Steffens, D. C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1690 · Cited by 136 · cited 1×
“Paige and colleagues [84] compared gas chromatography– mass spectrometry profiles of plasma extracts from depressed, remitted, and never-depressed older adults, revealing differences in levels of several fatty acids, glycerol, and γ-aminobutyric acid.”
BackgroundCostafreda, S. G., Khanna, A., Mourao-Miranda, J., & Fu, C. H. Y. (2009) · NeuroReport · doi:10.1097/wnr.0b013e3283294159 · Cited by 129 · cited 1×
“Studies that have used baseline neural reactivity to emotional facial expressions as a predictor of treatment response generally have been underpowered, but encouraging signs indicate that this task [36, 37] and analogous tasks [38] may be of utility for prediction.”
BackgroundHippocampal volume and 2-year outcome in depression
Kronmüller, K.-T., Pantel, J., Köhler, S., Victor, D., Giesel, F., Magnotta, V. A., Mundt, C., Essig, M., & Schröder, J. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.040378 · Cited by 107 · cited 1×
“In another prospective study, larger hippocampal volume was associated with a lower probability of relapse in men at a 2-year follow-up [25].”
BackgroundAltered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression
Iga, J.-I., Ueno, S.-I., Yamauchi, K., Numata, S., Kinouchi, S., Tayoshi-Shibuya, S., Song, H., & Ohmori, T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.12.014 · Cited by 105 · cited 1×
“In some small studies, antidepressant treatment tended to normalize gene expression patterns, and the degree of normalization was proportional to the degree of symptom improvement [75, 78, 79].”
Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results
Laje, G., Perlis, R. H., Rush, A. J., & McMahon, F. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1446 · Cited by 89
Cited by
Cross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud, A. M., Zotti, R. J., Shehzad, Z., Gueorguieva, R., Johnson, M. K., Trivedi, M. H., Cannon, T. D., Krystal, J. H., & Corlett, P. R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00471-x · Cited by 676
Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 474
A wavelet-based technique to predict treatment outcome for Major Depressive Disorder
Mumtaz, W., Xia, L., Mohd Yasin, M. A., Azhar Ali, S. S., & Malik, A. S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171409 · Cited by 268
Belzeaux, R., Bergon, A., Jeanjean, V, Loriod, B., Formisano-Tréziny, C., Verrier, L., Loundou, A., Baumstarck-Barrau, K., Boyer, L., Gall, V, et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.112 · Cited by 219
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
“Predictive biomarkers are being studied with the goal of differentiating treatment responders and nonresponders to antidepressants [37,38].”
Background
Metadata
- Authors
- Leuchter, A. F., Cook, I. A., Hamilton, S. P., Narr, K. L., Toga, A., Hunter, A. M., Faull, K., Whitelegge, J., Andrews, A. M., Loo, J., Way, B., Nelson, S. F., Horvath, S., & Lebowitz, B. D.
- Venue
- Current Psychiatry Reports
- Published
- 2010-10-21
- Volume
- 12
- Issue
- 6
- Pages
- 553-562
- ISSN
- 1523-3812 (ISSN-L)
- 1535-1645
- OpenAlex
- W1994672146
- Cited by
- 140
- References
- 36
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.